logo for print

China’s Ozempic Test

Novo Nordisk, the maker of Ozempic, has enjoyed a China boom in recent years, commanding 77 percent of the market. But that kind of dominance...

Libel Lawfare

In recent years, several large Chinese companies have filed defamation suits against small organizations or individual researchers, leading to a strange reality: Even as the...

Broken Engagement

Our series of interviews with top U.S. policy makers of the last 30 years has revealed how and why the American approach towards China has...

A Son of Two Empires

In his new book, Edward Wong reflects on the nature of the American dream and the Chinese dream — and how he and his father...

The Clash of Constellations

In 2021, Beijing announced Guowang, its answer to SpaceX’s Starlink. But with very few updates about the project — apart from disciplinary inspections — it...

Access Denied

Jen Easterly, the eccentric director of the Cybersecurity and Infrastructure Security Agency (CISA), has huge support when it comes to her number one priority: fighting...

The Great EV Glut

The new U.S. tariffs on Chinese-made EVs are both unprecedented and largely performative since Chinese EVs haven't yet penetrated the U.S. market. The European Union,...

China Goes Global — Again

Chinese companies have decided that the best place to make money right now is outside of China. The phenomenon known as chu hai (出海), which...